Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness - Concepedia

Concepedia

Publication | Open Access

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

DOI Full Paper Access

26

Citations

21

References

2018

Year

Beth Woods, E.G. Sideris, Matthew R. Sydes, Melissa Gannon, Mahesh Parmar, Mymoona Alzouebi, Gerhardt Attard, Alison Birtle, Susannah Brock, Richard Cathomas,

European Urology Oncology

References

	Year	Citations

Page 1